Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the effect of combined heparin and aspirin compared with aspirin monotherapy in pregnant women with antiphospholipid syndrome and recurrent pregnancy loss. DATA SOURCES: We searched the PubMed database up to December 2009 for English-language studies using the key words "aspirin AND (heparin OR low molecular weight heparin), (antiphospholipid OR anticardiolipin OR aPL) AND pregnancy." METHODS OF STUDY SELECTION: Two hundred ninety- two studies were initially screened. Randomized controlled trials comparing the effect of heparin (unfractionated heparin or low molecular weight heparin) plus aspirin compared with aspirin alone on the live-birth rate in women with a history of at least two miscarriages and antiphospholipid antibodies were eligible. TABULATION, INTEGRATION, AND RESULTS: The pooled effect of unfractionated heparin and low molecular weight heparin was evaluable in three and two randomized controlled studies, respectively, with regard to live births, which was the major outcome. Overall, treatment effects were in favor of heparin against first-trimester losses (odd ratio [OR] 0.39, 95% confidence interval [CI] 0.24-0.65, number needed to treat 6). More specifically, unfractionated heparin displayed a significant effect (OR 0.26, 95% CI 0.14-0.48, number needed to treat 4), while the pooled effect of low molecular weight heparin was insignificant (OR 0.70, 95% CI 0.34-1.45). Combination therapy of either unfractionated heparin or low molecular weight heparin with aspirin failed to display any significant effect in the prevention of late-pregnancy losses. No significant differences were observed between treatment and control groups for any other outcomes. CONCLUSION: The combination of unfractionated heparin and aspirin confers a significant benefit in live births. However, the efficacy of low molecular weight heparin plus aspirin remains unproven, highlighting the urgent need for large controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two further meta-analyses showed similar reduction in recurrent miscarriage for the aspirin and UFH group (OR 0.26, 95% CI 0.14-0.48).164”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [164]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Weitz, J. I. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371007 · Cited by 1,533
Rai, R., Cohen, H., Dave, M., & Regan, L. (1997) · BMJ · doi:10.1136/bmj.314.7076.253 · Cited by 1,113
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Kutteh, W. H. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70610-5 · Cited by 803
Greer, I. A., & Nelson-Piercy, C. (2005) · Blood · doi:10.1182/blood-2005-02-0626 · Cited by 797
Estimation of a Common Effect Parameter from Sparse Follow-Up Data
Greenland, S., & Robins, J. M. (1985) · Biometrics · doi:10.2307/2530643 · Cited by 794
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Pabinger, I., Sofaer, S., & Hirsh, J. (2008) · Chest · doi:10.1378/chest.08-0761 · Cited by 793
Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation
Girardi, G., Redecha, P., & Salmon, J. E. (2004) · Nature Medicine · doi:10.1038/nm1121 · Cited by 680
Carreras, L., Machin, S., Deman, R., Defreyn, G., Vermylen, J., Spitz, B., & Van Assche, A. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92087-0 · Cited by 551
Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic Mechanism
Rand, J. H., Wu, X.-X., Andree, H. A. M., Lockwood, C. J., Guller, S., Scher, J., & Harpel, P. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370303 · Cited by 526
Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant
Empson, M. B., Lassere, M., Craig, J. C., & Scott, J. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002859.pub2 · Cited by 486
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment
Farquharson, R. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02165-8 · Cited by 427
Lester, E. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91358-1 · Cited by 363
LASKIN, C. A., SPITZER, K. A., CLARK, C. A., CROWTHER, M. R., GINSBERG, J. S., HAWKER, G. A., KINGDOM, J. C., BARRETT, J., & GENT, M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080763 · Cited by 352
Rai, R. S., Clifford, K., Cohen, H., & Regan, L. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135907 · Cited by 301
Ruiz-Irastorza, G., Khamashta, M. A., Castellino, G., & Hughes, G. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04239-2 · Cited by 257
Mak, A., Cheung, M. W.-L., Cheak, A. A.-C., & Ho, R. C.-M. (2010) · Rheumatology · doi:10.1093/rheumatology/kep373 · Cited by 255
Noble, L. S., Kutteh, W. H., Lashey, N., Franklin, R. D., & Herrada, J. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.002 · Cited by 234
Sebire, N. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.4.1067 · Cited by 196
Chamley, L., Duncalf, A., Mitchell, M., & Johnson, P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60080-3 · Cited by 166
Heparin and aspirin attenuate placental apoptosis in vitro: Implications for early pregnancy failure
Bose, P., Black, S., Kadyrov, M., Weissenborn, U., Neulen, J., Regan, L., & Huppertz, B. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.09.029 · Cited by 166
Placental pathology in systemic lupus erythematosus: A prospective study
Magid, M. S., Kaplan, C., Sammaritano, L. R., Peterson, M., Druzin, M. L., & Lockshin, M. D. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70277-7 · Cited by 162
Katsuragawa, H., Kanzaki, H., Inoue, T., Hirano, T., Mori, T., & Rote, N. S. (1997) · Biology of Reproduction · doi:10.1095/biolreprod56.1.50 · Cited by 160
Kutteh, W. H., & Ermel, L. D. (1996) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1996.tb00501.x · Cited by 156
Stephenson, M. D., Ballem, P. J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan, E., & Ensom, M. H. H. (2004) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30644-2 · Cited by 140
Simone, N. D., Raschi, E., Testoni, C., Castellani, R., D'Asta, M., Shi, T., Krilis, S. A., Caruso, A., & Meroni, P. L. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.021444 · Cited by 137
Treatment of pregnant patients with antiphospholipid syndrome
Tincani, A., Branch, W., Levy, R. A., Piette, J. C., Carp, H., Rai, R. S., Khamashta, M., & Shoenfeld, Y. (2003) · Lupus · doi:10.1191/0961203303lu393oa · Cited by 121 · cited 1×
“Inclusion criteria were a priori defined to identify randomized controlled studies that (1) included pregnant women with antiphospholipid antibodies stratified to receive either aspirin plus heparin (low molecular weight heparin or unfractionated heparin) or aspirin only and (2) reported pregnancy outcome (pregnancy l…”
BackgroundAntiphospholipid Syndrome in Pregnancy: A Randomized, Controlled Trial of Treatment
Farquharson, R. G., Quenby, S. M., & Greaves, M. (2002) · Obstetrics & Gynecology · doi:10.1097/00006250-200212000-00032 · Cited by 96
Bose, P., Black, S., Kadyrov, M., Bartz, C., Shlebak, A. A., Regan, L., & Huppertz, B. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.014 · Cited by 95
Franklin, R. D., & Kutteh, W. H. (2002) · Human Reproduction · doi:10.1093/humrep/17.11.2981 · Cited by 92
Activation of complement mediates antiphospholipid antibody-induced pregnancy loss
Salmon, J. E., Girardi, G., & Holers, V. M. (2003) · Lupus · doi:10.1191/0961203303lu397oa · Cited by 89
Lassere, M. N., & Empson, M. B. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.08.006 · Cited by 83 · cited 1×
“Inclusion criteria were a priori defined to identify randomized controlled studies that (1) included pregnant women with antiphospholipid antibodies stratified to receive either aspirin plus heparin (low molecular weight heparin or unfractionated heparin) or aspirin only and (2) reported pregnancy outcome (pregnancy l…”
BackgroundFranklin, R. (2003) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02520-6 · Cited by 72
Goel, N., Tuli, A., & Choudhry, R. (2006) · PubMed · Cited by 66
DI SIMONE, N., LUIGI, M. P., MARCO, D., FIORELLA, D. N., SILVIA, D., CLARA, D. M., & ALESSANDRO, C. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1422.054 · Cited by 66
Ermel, L. D., Marshburn, P. B., & Kutteh, W. H. (1995) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1995.tb01133.x · Cited by 57
Woodhams, B. J., Candotti, G., Shaw, R. W., & Kernoff, P. B. A. (1989) · Thrombosis Research · doi:10.1016/0049-3848(89)90460-x · Cited by 50
Takakuwa, K., Asano, K., Arakawa, M., Yasuda, M., Hasegawa, I., & Tanaka, K. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81475-6 · Cited by 41
Antiphospholipid Antibodies: Effects on Trophoblast and Endothelial Cells
D’Ippolito, S., Simone, N. D., Nicuolo, F. D., Castellani, R., & Caruso, A. (2007) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2007.00500.x · Cited by 36
Low-Molecular-Weight Heparins: Mechanisms, Trials, and Role in Contemporary Interventional Medicine
Canales, J. F., & Ferguson, J. J. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808010-00003 · Cited by 18
Happe, L. E., Farrelly, E., Stanford, R. H., & Sarnes, M. W. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0170-1 · Cited by 12
Low-molecular-weight heparin for thromboprophylaxis
Camporese, G., & Bernardi, E. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32832f5d9d · Cited by 7
Cited by
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.048 · Cited by 1,308
“The combination of twice daily unfractionated heparin and low-dose aspirin appears to confer a significant benefit in pregnancies with aPLs and otherwise unexplained recurrent pregnancy loss; comparable efficacy of low molecular weight heparin has not been established (38, 39).”
BackgroundESHRE guideline: recurrent pregnancy loss
The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Nelen, W., Peramo, B., Quenby, S., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy004 · Cited by 1,002
“…low dose aspirin (75 – 100 mg/day), starting before conception, and a prophylactic dose heparin (unfractionated heparin [UFH] or low molecular weight heparin [LMWH]) starting at date of a positive pregnancy test, over no treatment (Empson et al. , 2005; Mak et al. , 2010; Ziakas et al. , 2010).”
Andreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., Doria, A., Fischer-Betz, R., Forger, F., Moraes-Fontes, M. F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209770 · Cited by 945
Melamed, N., Baschat, A., Yinon, Y., Athanasiadis, A., Mecacci, F., Figueras, F., Berghella, V., Nazareth, A., Tahlak, M., McIntyre, H. D., et al. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13522 · Cited by 570
Dechartres, A., Boutron, I., Trinquart, L., Charles, P., & Ravaud, P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00006 · Cited by 307
Metadata
- Authors
- Ziakas, P. D., Pavlou, M., & Voulgarelis, M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Venue
- Obstetrics & Gynecology
- Published
- 2010-06
- Volume
- 115
- Issue
- 6
- Pages
- 1256-1262
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2083779542
- Cited by
- 185
- References
- 47
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 11 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 16 · 2018: 11 · 2017: 17 · 2016: 16 · 2015: 14 · 2014: 17 · 2013: 13 · 2012: 12
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- antiphospholipid syndrome, recurrent pregnancy loss, heparin, aspirin, low molecular weight heparin, unfractionated heparin, live birth rate, miscarriage prevention, combination anticoagulant therapy, pregnancy
- MeSH terms
- Abortion, Habitual, Aspirin, Drug Therapy, Combination, Female, Fibrinolytic Agents, Heparin, Humans, Pregnancy, Antiphospholipid Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.